溶瘤病毒
癌症研究
医学
肿瘤微环境
活体显微镜检查
免疫疗法
血栓形成
免疫系统
癌症
癌细胞
肿瘤细胞
光动力疗法
癌症治疗
肿瘤进展
遗传增强
病理
内皮干细胞
血管
癌症免疫疗法
免疫学
循环系统
转移
内皮
作者
Bin Yu,Lei Shi,Weiwang Duan,Dongmei Cui,Edwin R. Manuel,Wei Huang
标识
DOI:10.3389/fimmu.2025.1733164
摘要
Introduction In recent years, oncolytic bacterial therapy has emerged as a promising strategy in cancer research due to its unique advantages in tumor targeting and immune activation. Among various bacterial candidates, Salmonella demonstrates exceptional potential owing to its amenability to genetic engineering and its capacity to serve as an efficient vector for therapeutic gene delivery. However, the precise spatiotemporal dynamics of the interaction between Salmonella and tumor vasculature, as well as the mechanisms by which Salmonella targets and colonizes tumors via the circulatory system, remain to be fully elucidated. Methods A dorsal skin-fold window chamber model was established in nude mice bearing tdTomato-labeled MDA-MB-231 xenografts. Real-time intravital imaging was used to track tumor growth, angiogenesis, and EGFP-labeled YB1 distribution after intravenous administration. Results Following intravenous injection, YB1 was retained in local vascular regions within the characteristically disordered tumor vascular network, such as "Shoulder Structure" or "Maze Structure". This physical entrapment facilitated direct interaction between YB1 and vascular endothelial cells, leading to endothelial damage and subsequent intratumoral vascular thrombosis. This process effectively blocked the tumor's blood supply and induced local hypoxia. Importantly, the formation of thrombosis and the hypoxic microenvironment further promoted the colonization and proliferation of YB1 within the tumor parenchyma, ultimately achieving effective tumor targeting and regression. Discussion This study reveals the novel mechanism of YB1's tumor targeting and colonization from the perspective of interaction with tumor vasculature. These findings providing critical theoretical support for the future design of more efficient and safer oncolytic bacterial therapies and lay a foundation for YB1’s clinical optimization.
科研通智能强力驱动
Strongly Powered by AbleSci AI